List of securities and quantities for demat auction settlement number 811 dated February 3, 2026.
Impact
Medium
Severity
Medium
Justification
Standard demat auction settlement notice affecting multiple securities with specific quantities to be auctioned. Relevant for brokers and participants with pending delivery obligations.
List of securities and quantities to be auctioned in demat auction for settlement number 811 dated February 3, 2026.
Impact
Medium
Severity
Medium
Justification
Routine demat auction notice affecting multiple securities across various companies. Important for brokers and traders with outstanding delivery obligations in settlement 811.
BSE demat auction settlement details for 811 listing securities pending delivery with quantities to be auctioned across multiple scrips.
Impact
Medium
Severity
Medium
Justification
Routine demat auction process affecting multiple securities with delivery obligations pending from settlement 811. Impact limited to specific scrips and quantities but requires broker attention for settlement completion.
BSE demat auction listing for settlement number 811 dated February 3, 2026, covering securities shortages across multiple scrips requiring auction settlement.
Impact
Medium
Severity
Medium
Justification
Routine demat auction for settlement failures affecting 141 scrips with varying quantities. Material impact on affected trading members who must participate in auction to fulfill delivery obligations.
BSE announces changes to Long Term ASM Framework with 6 securities newly shortlisted, 2 moved to higher stages, 6 moved to lower stages, and 7 securities moving out of the framework effective February 01, 2026.
Impact
Medium
Severity
Medium
Justification
Affects 21 securities through entry, exit, and stage changes in LT-ASM framework, impacting trading conditions and surveillance measures for these stocks.
16,61,000 new equity shares of NOVELIX PHARMACEUTICALS LIMITED listed on BSE effective January 1, 2026, issued through preferential allotment via warrant conversion.
Impact
Low
Severity
Low
Justification
Routine listing of preferentially allotted shares for a single company with limited market-wide impact.
16,61,000 equity shares of Novelix Pharmaceuticals Limited listed on BSE effective January 1, 2026, issued through preferential allotment via warrant conversion.
Impact
Low
Severity
Low
Justification
Routine listing of new securities for a single company through preferential allotment. Limited market-wide impact.
16,61,000 equity shares of Novelix Pharmaceuticals Limited listed on BSE with effect from January 1, 2026, issued on preferential basis pursuant to warrant conversion.
Impact
Low
Severity
Low
Justification
Routine listing of preferential shares after warrant conversion with limited market impact due to lock-in requirements